Linker Information
General Information of This Linker
| Linker ID |
LIN0WCLMP
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Cys-11 ADC linker
|
|||||
| Linker Type |
Thiol-sensitive linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C59H91N15O17
|
|||||
| Isosmiles |
CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)Cc1cc(NC(=O)C(C)NC(=O)C(NC(=O)CCCCCN2C(=O)C=CC2=O)C(C)C)ccc1CO
|
|||||
| InChI |
InChI=1S/C59H91N15O17/c1-38(2)57(62-44(77)19-17-16-18-24-74-45(78)22-23-46(74)79)59(91)60-39(3)58(90)61-43-21-20-41(37-75)42(25-43)26-64(6)48(81)28-66(8)50(83)30-68(10)52(85)32-70(12)54(87)34-72(14)56(89)36-73(15)55(88)35-71(13)53(86)33-69(11)51(84)31-67(9)49(82)29-65(7)47(80)27-63(5)40(4)76/h20-23,25,38-39,57,75H,16-19,24,26-37H2,1-15H3,(H,60,91)(H,61,90)(H,62,77)
|
|||||
| InChIKey |
CQOKSZWYZOLDCC-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1282.465
|
Polar area
|
368.32
|
||
|
Complexity
|
1281.671736
|
xlogp Value
|
-4.1894
|
|||
|
Heavy Count
|
91
|
Rot Bonds
|
35
|
|||
|
Hbond acc
|
17
|
Hbond Donor
|
4
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
PRO1184 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05579366 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
Phase 1/2 study of PRO1184 in patients with locally advanced and/or metastatic solid tumors.
|
||||
PRO-1160 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05721222 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL).
|
||||
References